These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26413494)

  • 1. Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force.
    Soto M; Abushakra S; Cummings J; Siffert J; Robert P; Vellas B; Lyketsos CG;
    J Prev Alzheimers Dis; 2015 Sep; 2(3):184-188. PubMed ID: 26413494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.
    Sano M; Soto M; Carrillo M; Cummings J; Hendrix S; Mintzer J; Porsteinsson A; Rosenberg P; Schneider L; Touchon J; Aisen P; Vellas B; Lyketsos C
    J Prev Alzheimers Dis; 2018; 5(2):98-102. PubMed ID: 29616702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.
    Soto M; Andrieu S; Nourhashemi F; Ousset PJ; Ballard C; Robert P; Vellas B; Lyketsos CG; Rosenberg PB
    Int Psychogeriatr; 2014 Sep; ():1-17. PubMed ID: 25226218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.
    Vellas B; Bateman R; Blennow K; Frisoni G; Johnson K; Katz R; Langbaum J; Marson D; Sperling R; Wessels A; Salloway S; Doody R; Aisen P;
    J Prev Alzheimers Dis; 2015 Jun; 2(2):128-135. PubMed ID: 26247004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTAD Task Force Paper: Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force.
    Soto M; Rosenberg P; Ballard C; Vellas B; Miller D; Gauthier S; Carrillo MC; Lyketsos C; Ismail Z
    J Prev Alzheimers Dis; 2024; 11(1):56-64. PubMed ID: 38230717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations.
    Vellas B; Sampaio C; Bateman R; Boxer A; Carrillo MC; Cummings J; Dubois B; Hampel H; Katz R; Khachaturian Z; Gauthier S; Johnson K; Karlawish J; Mintun M; Petersen R; Rafii M; Robert P; Schneider LS; Siemers E; Sperling R; Tariot P; Touchon J; Weiner M; Andrieu S; Aisen P
    J Prev Alzheimers Dis; 2014; 1(2):110-116. PubMed ID: 29255837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
    De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
    J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
    Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
    CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.
    Aisen P; Touchon J; Andrieu S; Boada M; Doody R; Nosheny RL; Langbaum JB; Schneider L; Hendrix S; Wilcock G; Molinuevo JL; Ritchie C; Ousset PJ; Cummings J; Sperling R; DeKosky ST; Lovestone S; Hampel H; Petersen R; Legrand V; Egan M; Randolph C; Salloway S; Weiner M; Vellas B
    J Prev Alzheimers Dis; 2016; 3(2):68-74. PubMed ID: 29210442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
    De Mauleon A; Ismail Z; Rosenberg P; Miller D; Cantet C; O'Gorman C; Vellas B; Lyketsos C; Soto M
    Alzheimers Dement; 2021 Oct; 17(10):1687-1697. PubMed ID: 34132461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.